Search results for " secondary prevention"

showing 4 items of 14 documents

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

In-Hospital and One-Year Outcomes of Patients after Early and Late Resuscitated Cardiac Arrest Complicating Acute Myocardial Infarction—Data fr…

2022

The prognostic role of early (less than 48 h) resuscitated cardiac arrest (ErCA) complicating acute myocardial infarction (AMI) is still controversial. The present study aimed to analyse the short-term and one-year outcomes of patients after ErCA and late resuscitated cardiac arrest (LrCA) compared to patients without cardiac arrest (CA) complicating AMI. Data from the prospective nationwide Polish Registry of Acute Coronary Syndromes (PL-ACS) were used to assess patients with resuscitated cardiac arrest (rCA) after AMI. Baseline clinical characteristics and the predictors of all-cause death were assessed. The all-cause mortality rate, complications, performed procedures, and re-hospitalisa…

cardiac rehabilitationsecondary prevention of sudden cardiac deathdiabetes mellitus; ejection fraction; heart failure; myocardial infarctionlife-threatening ventricular arrhythmiaRMedicineacute coronary syndrome; cardiac rehabilitation; sudden cardiac death; life-threatening ventricular arrhythmia; early and late cardiac arrest; secondary prevention of sudden cardiac deathGeneral Medicineearly and late cardiac arrestsudden cardiac deathacute coronary syndromeJournal of Clinical Medicine; Volume 11; Issue 3; Pages: 609
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct